98%
921
2 minutes
20
Diabetic kidney disease (DKD) is the predominant etiology of end-stage renal disease (ESRD). Despite rigorous therapeutic interventions aimed at managing hyperglycemia, regulating blood pressure, and employing renin-angiotensin system inhibitors, the incidence of DKD remains high. Recent investigations have indicated a shift in the disease spectrum of DKD accompanied by significant advancements in the development of novel therapeutic options. Nevertheless, in addition to agents such as renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and mineralocorticoid receptor antagonists (MRA), there is currently no optimal strategy in contemporary medicine to effectively mitigate the progression of DKD. The application of TCM in the management of DKD has demonstrated its potential in delaying disease progression and enhancing patient quality of life, thereby playing a crucial role in the prevention and treatment of this condition. Clinical evidence supports its efficacy and safety profile. This article aimed to explore the TCM approach to DKD, focusing on aspects such as etiology, pathogenesis, syndrome differentiation, and comprehensive treatment, while also analyzing the latest research developments in the pathophysiology of DKD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276746 | PMC |
http://dx.doi.org/10.2147/DMSO.S523094 | DOI Listing |
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
Circ Cardiovasc Interv
September 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy (F.T., G.A., M.G., K.S., D.D., G.S., M.C.).
Mitral regurgitation is the most common valve disease worldwide. Despite its wide success in inoperable or high-risk surgical patients, transcatheter edge-to-edge repair remains limited by some anatomic features and the not negligible rate of significant residual regurgitation. Transcatheter mitral valve replacement has emerged as a viable alternative that promises to overcome these issues, but its development has been progressing slowly.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Department of Internal Medicine, Dubai Hospital, Dubai Health, Dubai, Dubai, United Arab Emirates.
Introduction: Primary central nervous system vasculitis (primary CNS vasculitis) is a rare inflammatory disorder that affects small-to-medium-sized cerebral vessels, often leading to recurrent strokes. Diagnosis is vague due to non-specific neurological symptoms. Imaging findings, cerebrospinal fluid (CSF) analysis and exclusion of systemic vasculitis are essential for diagnosis.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Division of Internal Medicine, University Hospital of Basel, Basel, Switzerland.
Unlabelled: Encephalitis is a potentially life-threatening condition with infectious or autoimmune aetiologies. Autoimmune encephalitis includes paraneoplastic variants associated with specific onconeural antibodies such as anti-Hu, frequently linked to malignancies. Herpes simplex virus type 1 (HSV-1) is the leading infectious cause in adults.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDF